Literature DB >> 8670421

Central hypotensive effects of the alpha2a-adrenergic receptor subtype.

L B MacMillan1, L Hein, M S Smith, M T Piascik, L E Limbird.   

Abstract

alpha2-Adrenergic receptors (alpha2ARs) present in the brainstem decrease blood pressure and are targets for clinically effective antihypertensive drugs. The existence of three alpha2AR subtypes, the lack of subtype-specific ligands, and the cross-reactivity of alpha2AR agonists with imidazoline receptors has precluded an understanding of the role of individual alpha2AR subtypes in the hypotensive response. Gene targeting was used to introduce a point mutation into the alpha2aAR subtype in the mouse genome. The hypotensive response to alpha2AR agonists was lost in the mutant mice, demonstrating that the alpha2aAR subtype plays a principal role in this response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670421     DOI: 10.1126/science.273.5276.801

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  78 in total

1.  Effect of chronic clonidine treatment on transmitter release from sympathetic varicosities of the guinea-pig vas deferens.

Authors:  D Knight; T C Cunnane; N A Lavidis
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 2.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

3.  The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy.

Authors:  L S Stone; L B MacMillan; K F Kitto; L E Limbird; G L Wilcox
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

4.  Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo.

Authors:  P P Lakhlani; L B MacMillan; T Z Guo; B A McCool; D M Lovinger; M Maze; L E Limbird
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Respective contributions of alpha-adrenergic and non-adrenergic mechanisms in the hypotensive effect of imidazoline-like drugs.

Authors:  V Bruban; J Feldman; H Greney; M Dontenwill; S Schann; C Jarry; M Payard; J Boutin; E Scalbert; B Pfeiffer; P Renard; P Vanhoutte; P Bousquet
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 6.  Synergies at the synapse.

Authors:  Lee E Límbírd
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

7.  Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.

Authors:  Masato Hara; Ryuichi Fukui; Eriko Hieda; Mahomi Kuroiwa; Helen S Bateup; Tatsuhiko Kano; Paul Greengard; Akinori Nishi
Journal:  J Neurochem       Date:  2010-03-04       Impact factor: 5.372

8.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Modulatory inputs on sympathetic neurons in the rostral ventrolateral medulla in the rat.

Authors:  Antonio R Granata
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

10.  alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.

Authors:  K Orito; M Kishi; T Imaizumi; T Nakazawa; A Hashimoto; T Mori; T Kambe
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.